Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock (RYZB) Stock Overview

Explore RayzeBio, Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.

RYZB●NASDAQ
HealthcareBiotechnology
$62.49
$0.01(0.02%)
U.S. Market is Open · 14:10

RayzeBio, Inc. Common Stock (RYZB)

Meyka AI Score

Z

Key Financials

Market Cap3.8B
P/E Ratio-35.71
EPS (TTM)$-1.08
ROE0.83%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$305.20

RYZB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of RayzeBio, Inc. Common Stock (NASDAQ: RYZB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, RayzeBio, Inc. Common Stock's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RYZB on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $305.20 for the NASDAQ listing.

Key metrics behind RayzeBio, Inc. Common Stock's NASDAQ-traded stock include a P/E ratio of -35.71 and a market capitalization of 3.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RYZB on the NASDAQ.

Price Performance (NASDAQ: RYZB)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
104.42%
6-Month Change
218.50%
Year-to-Date (YTD) Change
0.87%
1-Year Change
160.38%
3-Year Change
160.38%
5-Year Change
160.38%
All-Time (Max) Change
160.38%

Contact Information

NaN
NaN
NaN, NaN, DE, NaN

Company Facts

880 Employees
IPO DateSep 15, 2023
CountryUS

Frequently Asked Questions